US Stock MarketDetailed Quotes

GPCR Structure Therapeutics

Watchlist
  • 27.900
  • -2.070-6.91%
Close Dec 20 16:00 ET
  • 27.890
  • -0.010-0.04%
Post 20:01 ET
1.60BMarket Cap-14.45P/E (TTM)

Structure Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
75.31%45.84M
28.20%33.32M
62.93%32.02M
95.53%102.78M
139.23%30.99M
105.98%26.15M
86.15%25.99M
51.71%19.65M
39.43%52.56M
-2.40%12.96M
Selling and administrative expenses
53.40%13.24M
71.32%11.27M
74.03%11.34M
99.61%32.67M
138.29%10.95M
144.27%8.63M
74.01%6.58M
46.05%6.51M
90.66%16.37M
36.50%4.6M
-General and administrative expense
53.40%13.24M
71.32%11.27M
74.03%11.34M
99.61%32.67M
138.29%10.95M
144.27%8.63M
74.01%6.58M
46.05%6.51M
90.66%16.37M
36.50%4.6M
Research and development costs
86.11%32.6M
13.60%22.05M
57.43%20.68M
93.69%70.1M
139.74%20.04M
91.21%17.52M
90.66%19.41M
54.67%13.14M
24.33%36.19M
-15.62%8.36M
Operating profit
-75.31%-45.84M
-28.20%-33.32M
-62.93%-32.02M
-95.53%-102.78M
-139.23%-30.99M
-105.98%-26.15M
-86.15%-25.99M
-51.71%-19.65M
-39.43%-52.56M
2.40%-12.96M
Net non-operating interest income expense
344.61%11.95M
159.65%7.34M
253.62%6.01M
965.31%13.39M
585.79%6.18M
670.20%2.69M
3,617.11%2.83M
2,562.32%1.7M
1,130.33%1.26M
90,200.00%901K
Total other finance cost
-344.61%-11.95M
-159.65%-7.34M
-253.62%-6.01M
-965.31%-13.39M
-585.79%-6.18M
-670.20%-2.69M
-3,617.11%-2.83M
-2,562.32%-1.7M
-1,130.33%-1.26M
-90,200.00%-901K
Other net income (expense)
Income before tax
-44.46%-33.89M
-12.17%-25.98M
-44.89%-26.01M
-74.22%-89.38M
-105.85%-24.82M
-90.03%-23.46M
-66.83%-23.16M
-37.85%-17.95M
-35.66%-51.3M
9.19%-12.06M
Income tax
-77.28%92K
-55.08%53K
16.00%29K
1,288.24%236K
-73.33%-312K
454.79%405K
84.38%118K
-58.33%25K
-92.64%17K
-322.22%-180K
Net income
-42.39%-33.98M
-11.83%-26.03M
-44.85%-26.04M
-74.63%-89.62M
-106.34%-24.5M
-92.17%-23.86M
-66.91%-23.28M
-37.41%-17.98M
-34.88%-51.32M
-22.25%-11.88M
Net income continuous Operations
-42.39%-33.98M
-11.83%-26.03M
-44.85%-26.04M
-74.63%-89.62M
-106.34%-24.5M
-92.17%-23.86M
-66.91%-23.28M
-37.41%-17.98M
-34.88%-51.32M
11.09%-11.88M
Minority interest income
Net income attributable to the parent company
-42.39%-33.98M
-11.83%-26.03M
-44.85%-26.04M
-74.63%-89.62M
-106.34%-24.5M
-92.17%-23.86M
-66.91%-23.28M
-37.41%-17.98M
-28.28%-51.32M
-1.73%-11.88M
Preferred stock dividends
Other preferred stock dividends
0
-59.68%1.52M
0
Net income attributable to common stockholders
-42.39%-33.98M
-11.83%-26.03M
-44.85%-26.04M
-69.62%-89.62M
-106.34%-24.5M
-92.17%-23.86M
-50.55%-23.28M
-37.41%-17.98M
-20.73%-52.84M
23.04%-11.88M
Basic earnings per share
4.76%-0.6
10.00%-0.54
24.00%-0.57
-75.89%-2.43
-54.58%-0.48
-29.29%-0.63
1.12%-0.6
-46.10%-0.75
19.56%-1.3816
48.72%-0.3105
Diluted earnings per share
4.76%-0.6
10.00%-0.54
24.00%-0.57
-75.89%-2.43
-54.58%-0.48
-29.29%-0.63
1.12%-0.6
-46.10%-0.75
19.56%-1.3816
48.72%-0.3105
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 75.31%45.84M28.20%33.32M62.93%32.02M95.53%102.78M139.23%30.99M105.98%26.15M86.15%25.99M51.71%19.65M39.43%52.56M-2.40%12.96M
Selling and administrative expenses 53.40%13.24M71.32%11.27M74.03%11.34M99.61%32.67M138.29%10.95M144.27%8.63M74.01%6.58M46.05%6.51M90.66%16.37M36.50%4.6M
-General and administrative expense 53.40%13.24M71.32%11.27M74.03%11.34M99.61%32.67M138.29%10.95M144.27%8.63M74.01%6.58M46.05%6.51M90.66%16.37M36.50%4.6M
Research and development costs 86.11%32.6M13.60%22.05M57.43%20.68M93.69%70.1M139.74%20.04M91.21%17.52M90.66%19.41M54.67%13.14M24.33%36.19M-15.62%8.36M
Operating profit -75.31%-45.84M-28.20%-33.32M-62.93%-32.02M-95.53%-102.78M-139.23%-30.99M-105.98%-26.15M-86.15%-25.99M-51.71%-19.65M-39.43%-52.56M2.40%-12.96M
Net non-operating interest income expense 344.61%11.95M159.65%7.34M253.62%6.01M965.31%13.39M585.79%6.18M670.20%2.69M3,617.11%2.83M2,562.32%1.7M1,130.33%1.26M90,200.00%901K
Total other finance cost -344.61%-11.95M-159.65%-7.34M-253.62%-6.01M-965.31%-13.39M-585.79%-6.18M-670.20%-2.69M-3,617.11%-2.83M-2,562.32%-1.7M-1,130.33%-1.26M-90,200.00%-901K
Other net income (expense)
Income before tax -44.46%-33.89M-12.17%-25.98M-44.89%-26.01M-74.22%-89.38M-105.85%-24.82M-90.03%-23.46M-66.83%-23.16M-37.85%-17.95M-35.66%-51.3M9.19%-12.06M
Income tax -77.28%92K-55.08%53K16.00%29K1,288.24%236K-73.33%-312K454.79%405K84.38%118K-58.33%25K-92.64%17K-322.22%-180K
Net income -42.39%-33.98M-11.83%-26.03M-44.85%-26.04M-74.63%-89.62M-106.34%-24.5M-92.17%-23.86M-66.91%-23.28M-37.41%-17.98M-34.88%-51.32M-22.25%-11.88M
Net income continuous Operations -42.39%-33.98M-11.83%-26.03M-44.85%-26.04M-74.63%-89.62M-106.34%-24.5M-92.17%-23.86M-66.91%-23.28M-37.41%-17.98M-34.88%-51.32M11.09%-11.88M
Minority interest income
Net income attributable to the parent company -42.39%-33.98M-11.83%-26.03M-44.85%-26.04M-74.63%-89.62M-106.34%-24.5M-92.17%-23.86M-66.91%-23.28M-37.41%-17.98M-28.28%-51.32M-1.73%-11.88M
Preferred stock dividends
Other preferred stock dividends 0-59.68%1.52M0
Net income attributable to common stockholders -42.39%-33.98M-11.83%-26.03M-44.85%-26.04M-69.62%-89.62M-106.34%-24.5M-92.17%-23.86M-50.55%-23.28M-37.41%-17.98M-20.73%-52.84M23.04%-11.88M
Basic earnings per share 4.76%-0.610.00%-0.5424.00%-0.57-75.89%-2.43-54.58%-0.48-29.29%-0.631.12%-0.6-46.10%-0.7519.56%-1.381648.72%-0.3105
Diluted earnings per share 4.76%-0.610.00%-0.5424.00%-0.57-75.89%-2.43-54.58%-0.48-29.29%-0.631.12%-0.6-46.10%-0.7519.56%-1.381648.72%-0.3105
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--
Heat List
US
Overall
Symbol
Price
% Chg

No Data

Investment Theme Weight Loss Drugs
Weight Loss Drugs
Intraday-4.61%